| Abstrakt: |
xekizumab is a monoclonal antibody targeting IL-17, and approved for the treatment of psoriasis, psoriatic arthritis, ankylosing spondylitis, and axial spondyloarthritis. Despite elevated IL-17 levels in the intestinal mucosa and serum of IBD patients, IL-17 inhibition had failed to demonstrate clinical efficacy for IBD treatment. Recent studies identified a rare association (<1%) of anti-IL-17 agents with the exacerbation or new-onset of IBD. However, infectious colitis can also mimic ixekizumab-related IBD in some patients. We present a case of a 39-year-old man who developed diarrhea and abdominal pain following the use of ixekizumab. He suffered from severe psoriasis and underwent immunosuppressive treatment for three years, although skin lesions persisted. Thus, all oral medications were discontinued, and ixekizumab was initiated. However, he developed persistent diarrhea after 4 doses of ixekizumab administration. Given the history of frequent bloody loose stools, the patient was initially suspected as new-onset IBD associated with ixekizumab. However, the colonoscopic biopsy revealed amebic colitis. After metronidazole treatment, the patient was recovered from diarrhea and could continue ixekizumab treatment. Recognizing the potential association between ixekizumab treatment and development of IBD, all patients should be screened with detailed personal and family histories before starting ixekizumab therapy. However, other causes such as amebic colitis also should be considered. [ABSTRACT FROM AUTHOR] |
